| $381M | ||
| $350M | ||
| $215M | ||
| $107M | ||
| $100M | ||
| $91M |
Buys | $0 | 0 | 0 |
Sells | $58,911,062 | 5 | 100 |
| Oltmans Curtis Gale | Chief Legal Officer | 0 | $0 | 1 | $44,600 | $-44,600 |
| Gould Robert J | director | 0 | $0 | 3 | $489,441 | $-489,441 |
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 0 | $0 | 1 | $58.38M | $-58.38M |
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
Over the last 12 months, insiders at Fulcrum Therapeutics, Inc. have bought $0 and sold $58.91M worth of Fulcrum Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Fulcrum Therapeutics, Inc. have bought $13.54M and sold $12.67M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 43,360 shares for transaction amount of $492,028 was made by Sapir Alex (See Remarks) on 2024‑03‑04.
| 2026-02-02 | Sale | Gould Robert J | director | 15,000 0.0277% | $10.72 | $160,857 | -29.57% | |
| 2026-01-02 | Sale | Gould Robert J | director | 15,000 0.0266% | $10.87 | $163,089 | -28.30% | |
| 2025-12-15 | Sale | Oltmans Curtis Gale | Chief Legal Officer | 3,452 0.0064% | $12.92 | $44,600 | -38.54% | |
| 2025-12-08 | Sale | RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 4.18M 8.3051% | $13.98 | $58.38M | -38.41% | |
| 2025-11-19 | Sale | Gould Robert J | director | 15,000 0.0266% | $11.03 | $165,495 | -28.15% | |
| 2025-05-08 | Sale | Tourangeau Greg | Principal Accounting Officer | 498 0.0009% | $5.06 | $2,520 | +45.47% | |
| 2024-05-07 | Sale | Tourangeau Greg | Principal Accounting Officer | 236 0.0004% | $7.76 | $1,831 | -47.02% | |
| 2024-03-08 | Sale | Tourangeau Greg | Vice President, Finance | 4,884 0.0084% | $11.72 | $57,219 | -44.40% | |
| 2024-03-04 | Sapir Alex | See Remarks | 43,360 0.0707% | $11.35 | $492,028 | -44.92% | ||
| 2023-05-10 | Sale | Tourangeau Greg | Principal Accounting Officer | 210 0.0004% | $3.31 | $695 | +46.48% | |
| 2023-01-20 | RA CAPITAL MANAGEMENT, L.P. | director | 1.92M 3.8009% | $13.00 | $25M | -68.65% | ||
| 2023-01-13 | Sale | Gould Robert J | Interim President & CEO | 6,766 0.0142% | $15.00 | $101,490 | -71.09% | |
| 2023-01-04 | RA CAPITAL MANAGEMENT, L.P. | director | 180,703 0.3049% | $7.28 | $1.31M | -52.17% | ||
| 2022-12-27 | RA CAPITAL MANAGEMENT, L.P. | director | 4,089 0.009% | $5.99 | $24,510 | -34.44% | ||
| 2022-12-19 | RA CAPITAL MANAGEMENT, L.P. | director | 98,787 0.2145% | $5.90 | $582,814 | -34.44% | ||
| 2022-12-16 | RA CAPITAL MANAGEMENT, L.P. | director | 1.34M 3.0203% | $5.42 | $7.27M | -25.98% | ||
| 2022-12-15 | RA CAPITAL MANAGEMENT, L.P. | director | 237,029 0.5283% | $5.50 | $1.3M | -27.74% | ||
| 2022-12-14 | RA CAPITAL MANAGEMENT, L.P. | director | 824,600 1.8392% | $5.46 | $4.5M | -27.21% | ||
| 2022-06-07 | Sale | Gould Robert J | 71,435 0.1753% | $8.09 | $577,895 | -23.70% | ||
| 2022-06-02 | Sale | Gould Robert J | 16,689 0.043% | $7.92 | $132,162 | -16.89% |
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 6053960 11.188% | $21.25M | 7 | 1 | |
| Gould Robert J | director | 454864 0.8406% | $1.6M | 0 | 24 | |
| Oltmans Curtis Gale | Chief Legal Officer | 10252 0.0189% | $35,984.52 | 1 | 1 | +68.04% |
| LEVIN MARK J | 5962202 11.0184% | $20.93M | 1 | 0 | +2.11% | |
| Third Rock Ventures III, L.P. | 10 percent owner | 5962202 11.0184% | $20.93M | 1 | 0 | +2.11% |
| Third Rock Ventures IV, L.P. | 10 percent owner | 2343154 4.3302% | $8.22M | 1 | 0 | +2.11% |
| Casdin Capital, LLC | 10 percent owner | 604285 1.1167% | $2.12M | 1 | 0 | +2.11% |
| 6 Dimensions Capital, L.P. | 10 percent owner | 559821 1.0346% | $1.96M | 1 | 0 | +2.11% |
| Sanofi | 10 percent owner | 558035 1.0313% | $1.96M | 1 | 0 | +2.11% |
| Wallace Owen B. | Chief Scientific Officer | 127088 0.2349% | $446,078.88 | 0 | 6 | |
| GERAGHTY JAMES A | director | 90714 0.1676% | $318,406.14 | 1 | 0 | +68.04% |
| Cadavid Diego | SVP Clinical Development | 65714 0.1214% | $230,656.14 | 0 | 12 | |
| Sapir Alex | See Remarks | 43360 0.0801% | $152,193.60 | 1 | 0 | |
| Tourangeau Greg | Principal Accounting Officer | 14062 0.026% | $49,357.62 | 0 | 4 | |
| Thomson Peter G. | VP Finance & Accounting | 2300 0.0043% | $8,073.00 | 1 | 5 | +68.04% |
| Morabito Christopher | Chief Medical Officer | 1100 0.002% | $3,861.00 | 1 | 0 | +68.04% |
| Stuart Bryan | See Remarks | 0 0% | $0 | 0 | 2 | |
| Moxham Christopher | Chief Scientific Officer | 0 0% | $0 | 0 | 1 |
$9,456,760 | 65 | 2.69% | $213.61M | |
$20,234,041 | 17 | 2.09% | $206.46M | |
$448,999,793 | 15 | -19.99% | $176M | |
$1,037,470 | 13 | 78.00% | $195.83M | |
$156,530,514 | 13 | 45.71% | $196.46M | |
$15,799,576 | 12 | -39.52% | $207.42M | |
Fulcrum Therapeutics, Inc. (FULC) | $19,167,169 | 10 | 28.48% | $189.93M |
$344,394 | 8 | -22.26% | $177.53M | |
$119,804,612 | 8 | -17.22% | $197.84M | |
$145,296,407 | 8 | -0.98% | $200.6M | |
$164,999,952 | 5 | -44.44% | $183.4M | |
$32,007,657 | 4 | -45.65% | $183.53M | |
$16,003,671 | 3 | 55.38% | $166.48M | |
$32,289,200 | 3 | -5.46% | $168.76M | |
$193,101 | 3 | -25.20% | $187.24M | |
$15,551,156 | 3 | 98.82% | $206.31M | |
$12,498 | 2 | 39.61% | $181.43M | |
$63,731 | 1 | -19.50% | $211.78M | |
$86,200 | 1 | -19.57% | $174.71M |
| Increased Positions | 103 | +66.88% | 23M | +43.09% |
| Decreased Positions | 67 | -43.51% | 10M | -18.1% |
| New Positions | 60 | New | 13M | New |
| Sold Out Positions | 19 | Sold Out | 881,636 | Sold Out |
| Total Postitions | 190 | +23.38% | 67M | +24.99% |
| Ra Capital Management, L.P. | $111,702.00 | 15.5% | 10.23M | 0 | 0% | 2025-09-30 |
| Suvretta Capital Management, Llc | $58,761.00 | 8.15% | 5.38M | +298,100 | +5.87% | 2025-09-30 |
| Tcg Crossover Management, Llc | $57,330.00 | 7.96% | 5.25M | 0 | 0% | 2025-09-30 |
| Nantahala Capital Management, Llc | $51,005.00 | 7.08% | 4.67M | +382,485 | +8.92% | 2025-09-30 |
| Blackrock, Inc. | $40,478.00 | 5.62% | 3.71M | -672,273 | -15.35% | 2025-09-30 |
| Vanguard Group Inc | $32,754.00 | 4.55% | 3M | -146,979 | -4.67% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $26,557.00 | 3.69% | 2.43M | -2M | -47% | 2025-09-30 |
| Balyasny Asset Management L.P. | $15,839.00 | 2.2% | 1.45M | +112,266 | +8.39% | 2025-09-30 |
| D. E. Shaw & Co., Inc. | $15,828.00 | 2.2% | 1.45M | +272,712 | +23.18% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $14,188.00 | 1.97% | 1.3M | -73,329 | -5.34% | 2025-09-30 |